Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peripheral T-cell lymphoma.

J O Armitage1, J P Greer, A M Levine

  • 1Department of Medicine, University of Nebraska Medical Center, Omaha 68105.

Cancer
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lactobacillus johnsonii supplementation attenuates respiratory viral infection via metabolic reprogramming and immune cell modulation.

Mucosal immunology·2017
Same author

High prevalence of viral hepatitis in a series of splenic marginal zone lymphomas from Romania.

Blood cancer journal·2016
Same author

Peripheral T-Cell Lymphoma-A Brief Review.

Leukemia & lymphoma·2016
Same author

Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma.

Leukemia·2016
Same author

The Medical Bookshelf.

Postgraduate medicine·2016
Same author

Problems+Solutions.

Postgraduate medicine·2016
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
Same journal

Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

Cancer·2026
Same journal

Most older patients with advanced cancer prioritize QOL over extending survival: A secondary analysis of the GAP70+ trial found that among adults aged 70 and older with advanced, noncurable cancer, nearly three-quarters prioritized maintaining QOL.

Cancer·2026
Same journal

Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer.

Cancer·2026
See all related articles

Peripheral T-cell lymphoma (PTCL) is common in US adults. Intensive chemotherapy offers a 45% 4-year survival, but Stage IV PTCL has a poor 10% disease-free survival rate.

Area of Science:

  • Oncology
  • Hematology
  • Clinical Medicine

Background:

  • Peripheral T-cell lymphoma (PTCL) is the predominant T-cell lymphoma subtype in adult United States populations.
  • PTCL exhibits diverse histological subtypes and frequently presents at advanced stages.

Purpose of the Study:

  • To review clinical data of PTCL patients to understand treatment outcomes and survival rates.
  • To evaluate the efficacy of multiagent chemotherapy in comparison to other treatment modalities for PTCL.

Main Methods:

  • Retrospective review of clinical data from 134 PTCL cases across three institutions.
  • Analysis of patient demographics, histological subtypes, disease stage, extranodal involvement, and treatment regimens.
  • Evaluation of complete remission rates and actuarial survival, stratified by treatment intensity and disease stage.

Related Experiment Videos

Main Results:

  • The median patient age was 57 years, with 59% males; 27% had a history of immune system disorders.
  • Stage IV disease was observed in 50% of patients, with bone marrow, skin, and lung being common extranodal sites.
  • Intensive chemotherapy yielded a 50% complete remission rate and 45% 4-year survival, contrasted with only 10% 4-year disease-free survival for Stage IV patients.

Conclusions:

  • Peripheral T-cell lymphomas share similarities with B-cell lymphomas but demonstrate lower disease-free survival rates.
  • Stage IV PTCL patients face a particularly challenging prognosis, necessitating further research into improved therapeutic strategies.